Intravenous Paricalcitol for Treatment of Secondary Hyperparathyroidism in Children on Hemodialysis

Paricalcitol decreased iPTH levels in children receiving hemodialysis with no significant changes in serum calcium, phosphorus, or Ca × P product values during the course of the study.